Xavier Montalban, MD, PhD, BA, Vall d’Hebron University Hospital, Barcelona, Spain, comments on unmet needs in the field of multiple sclerosis (MS), including neurodegeneration and progressive MS. Prof. Montalban highlights over 100 trials investigating the latest therapies for MS that are currently being conducted as well as novel targets and molecules being developed. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
